Posted On: 01/20/2016 12:54:25 PM
Post# of 30066
There is one diagnostic currently on the market for ovarian cancer - CA125 - owned by Roche Diagnostics.
It does $2 billion a year.
Sensitivity is the ability of the test to identify correctly those who have
a disease.
Specificity is the ability of the test to identify correctly those who do
not have a disease.
CA125 has the following:
Sensitivity - 50%
Specificity - 60%
OvaDx has the following:
Sensitivity - 93%
Specificity - 99%
The plan is to license or sell it to a large diagnostic company. AVDX has already been in talks with Roche Diagnostics.
It does $2 billion a year.
Sensitivity is the ability of the test to identify correctly those who have
a disease.
Specificity is the ability of the test to identify correctly those who do
not have a disease.
CA125 has the following:
Sensitivity - 50%
Specificity - 60%
OvaDx has the following:
Sensitivity - 93%
Specificity - 99%
The plan is to license or sell it to a large diagnostic company. AVDX has already been in talks with Roche Diagnostics.
(0)
(0)
